pipeline
ECI is focused on the development of products derived from human plasma and enhanced with mucoadhesive excipients.
Initial ophthalmic indications, the first two indications in our pipeline:
ECI-102 targets neurotrophic keratopathy (NK) and ECI-101 targets dry eye disease (DED).
Follow on ophthalmic indications:
ECI-102 and 101 may be leverageable for other rare and common indications respectively.
Additional product pipeline:
ECI intends to develop wound-healing products for the skin and other mucosal membranes. These include patches, gels, contact lenses, and slow-release products for the treatment of burns, ulcers, hard-to-heal wounds, dryness, and more.
ECI is also evaluating the use of our growth factor concentrates to store corneas for transplant and culture of human corneal endothelial and limbal cells.
eci product pipeline
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
disease states
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.